Clinical interventions targeting multiple mediators such as IFNα, IL-1β, TNF-α, IL-6, or BAFF have been largely disappointing (2), suggesting that other effector pathways may play a more dominant role in SLE pathogenesis or disease manifestations (3, 4). Here, IFNA1 is linked to systemic lupus erythematosus.